<code id='93AD03A395'></code><style id='93AD03A395'></style>
    • <acronym id='93AD03A395'></acronym>
      <center id='93AD03A395'><center id='93AD03A395'><tfoot id='93AD03A395'></tfoot></center><abbr id='93AD03A395'><dir id='93AD03A395'><tfoot id='93AD03A395'></tfoot><noframes id='93AD03A395'>

    • <optgroup id='93AD03A395'><strike id='93AD03A395'><sup id='93AD03A395'></sup></strike><code id='93AD03A395'></code></optgroup>
        1. <b id='93AD03A395'><label id='93AD03A395'><select id='93AD03A395'><dt id='93AD03A395'><span id='93AD03A395'></span></dt></select></label></b><u id='93AD03A395'></u>
          <i id='93AD03A395'><strike id='93AD03A395'><tt id='93AD03A395'><pre id='93AD03A395'></pre></tt></strike></i>

          hotspot

          hotspot

          author:comprehensive    Page View:9
          Illustration of a road with a chasm in the middle, indicating the end of a deal or a problem with a deal
          Adobe

          A deal is never really done until it’s done.

          On Tuesday, two different proposed insurance plan acquisitions on different sides of the country called it quits — one of them for the second time.

          advertisement

          California-based Medicare Advantage insurer SCAN Group has been trying to buy CareOregon, an insurer offering coverage to half a million people in Oregon’s state health plan, since January 2023. National insurer Elevance has also been trying to buy Blue Cross and Blue Shield of Louisiana since last January. The on-again, off-again purchase was paused in September 2023 because of state regulators’ concerns, but was resubmitted with a slightly different plan in December.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Wikipedia

          Cancer drug shortages should be causing more outrage
          Cancer drug shortages should be causing more outrage

          DrugshortagesareagrowingproblemintheU.S.,andashortageoflivesavingcancerdrugsinparticularhasreachedcr

          read more
          Lilly's Alzheimer's drug donanemab backed by FDA advisers
          Lilly's Alzheimer's drug donanemab backed by FDA advisers

          DarronCummings/APAdviserstotheFoodandDrugAdministrationvoted11-0onMondaytorecommendtheapprovalofadru

          read more
          Medicare details structure of new drug price negotiation program
          Medicare details structure of new drug price negotiation program

          MedicareonFridayreleasednewdetailsabouthowitsnewdrugpricenegotiationprogramwillwork,justtwomonthsbef

          read more

          Lilly's Alzheimer's drug donanemab backed by FDA advisers

          DarronCummings/APAdviserstotheFoodandDrugAdministrationvoted11-0onMondaytorecommendtheapprovalofadru